221 GSK Annual Report 2018 Strategic report Governance and remuneration Financial statements Investor information The ultimate liability for legal claims may vary from the amounts C Key accounting judgements and estimates provided and is dependent upon the outcome of litigation Legal and other disputes proceedings, investigations and possible settlement negotiations.
The company provides for anticipated settlement costs where The position could change over time and, therefore, there can be no management makes a judgement that an outow of resources is assurance that any losses that result from the outcome of any legal probable and a reliable estimate can be made of the likely outcome proceedings will not exceed the amount of the provisions reported of the dispute and legal and other expenses arising from claims in the companys financial statements by a material amount.
The estimated provisions take into account the specific circumstances of each dispute and relevant external advice, D Operating profit are inherently judgemental and could change substantially over time A fee of 12,000 2017 12,053 relating to the audit of the as each dispute progresses and new facts emerge.
company has been charged in operating profit.
The companys Directors, having taken legal advice, have established provisions after taking into account the relevant facts E Dividends and circumstances of each matter and in accordance with accounting requirements.
At 31 December 2018, provisions for legal The directors declared four interim dividends resulting in a dividend and other disputes amounted to 16 million 2017 27 million.
for the year of 80 pence, in line with the dividend for 2017.
For further details, see Note 16 to the Group financial statements, Dividends.
F Fixed assets investments 2018 2017 m m Shares in GlaxoSmithKline Services Unlimited 613 613 Shares in GlaxoSmithKline Holdings One Limited 18 18 Shares in GlaxoSmithKline Holdings Limited 17,888 17,888 Shares in GlaxoSmithKline Mercury Limited 33 33 18,552 18,552 Capital contribution relating to share-based payments 1,139 1,139 Contribution relating to contingent consideration 296 584 19,987 20,275 G Trade and other receivables 2018 2017 m m Amounts due within one year: UK Corporation tax recoverable 10 31 Other receivables 1 Amounts owed by Group undertakings 7,889 8,299 7,899 8,331 Amounts due after more than one year: Amounts owed by Group undertakings 495 384 8,394 8,715 H Short-term borrowings The 3.5 billion borrowing relates to a facility taken out in June 2018 as part of the financing of the buyout of the non-controlling interest in the Consumer Healthcare Joint Venture held by Novartis.
The facility has a maturity date of 1 December 2019.
I Trade and other payables 2018 2017 m m Amounts due within one year: Other creditors 567 438 Contingent consideration payable 14 346 Amounts owed to Group undertakings 29 53 610 837 The company has guaranteed debt issued by its subsidiary companies from two of which it receives fees.
In aggregate, the company has outstanding guarantees over 22.2 billion of debt instruments 2017 16.7 billion.
The amounts due from the subsidiary company in relation to these guarantee fees will be recovered over the life of the bonds and are disclosed within Trade and other receivables see Note G.
